Vioxx GMP Violations Cited In FDA Warning Letter Spur Merck Retraining

Inadequate sampling, testing, investigation and documentation of Merck's Vioxx (rofecoxib) lots are among good manufacturing practice violations cited in a June 27 FDA warning letter.